Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.


Inibitore di PIM e FLT


Current development phase: Phase I/II Acute myeloid leukemia

Phase I
Phase ii
Phase iii

MEN 1703 is a first-in-class orally available dual PIM and FLT3 kinase inhibitor discovered by Selvita and acquired by the Menarini Group at the beginning of 2017. 

The molecule has a unique activity profile for its ability of inhibiting both PIM kinase, important for cell cycle regulation, cell survival and tumorigenesis, and FLT3, a kinase involved in the onset and progression of acute myeloid leukemia (AML).

None of the molecules currently in clinical development has this dual activity.
MEN1703 started the Phase I/II clinical trial in patients with relapsed /refractory AML in March 2017.
Preclinical evidence supports clinical development not only in hematological tumors but also in solid tumors.
Technology Transfer of the manufacturing process from Selvita to Menarini is ongoing as well as preclinical studies aimed to support the design of additional clinical trials in AML and the selection of further indications in solid tumors and hematological malignancies.



Acute myeloid  leukemia represents around 30% of total blood tumors with an incidence of 30.000 new patients every year in Europe and with 2.000 patients in Italy alone.
Chemotherapy is the current best available treatment, it eliminate blasts from bone marrow and from peripheral blood.
But still Acute myeloid leukemia has a poor outcome since only 24% of patients survive after 5 years.There is a strong medical need for new, more effective therapy


Discover all of Menarini's products marketed in Italy. Read More »



Advanced Technology



Discover the leading Italian pharmaceutical company in the world. Read More »


Concession granted by Italian Ministry for Cultural Heritage and Activities Read more